CMS BALANCE Model and the Future of GLP-1 Drug Pricing
In late 2025, the Centers for Medicare and Medicaid Services (CMS) introduced the Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) model. This proposed pilot program aimed to manage and negotiate pricing for GLP-1 medications, targeting state Medicaid and Medicare Part D plans. Launched by the CMS Innovation Center, the model planned to begin with Medicaid in 2026 and extend to Medicare Part D in January 2027. However, CMS has decided to extend the Medicare GLP-1 Bridge program through the end of 2027, delaying the full-scale Medicare launch.
The postponement highlights issues related to implementing the model swiftly and aligns with evolving FDA drug approvals. The BALANCE model aimed to integrate weight-management GLP-1s into current Medicare and Medicaid frameworks. Yet, insurers encountered hurdles due to limited beneficiary data and unresolved issues around FDA indications, which overlapped with the Inflation Reduction Act’s Medicare Drug Negotiation Program (MDNP) and implications of new Section 402 demonstrations.
Recent FDA approvals for medications like Foundayo, Wegovy, and Zepbound have complicated Medicare's coverage strategy due to their varying therapeutic indications. These approvals affect how the same medication might be covered differently within the Part D benefit, increasing the complexity of the BALANCE model’s objectives.
Overlapping Models and Regulatory Considerations
The BALANCE model raises concerns about overlap with the MDNP, particularly as maximum fair pricing for some GLP-1 products begins in 2027. Questions around the model's necessity, given existing statutory frameworks, have emerged. CMS has suggested it might waive MDNP requirements to enable alternative rebate structures.
In this context, the extension of the Section 402 GLP-1 Bridge demonstration offers a transitional phase for collecting more data without disrupting current Medicare Part D processes. This allows CMS to gain insights on GLP-1 usage in a federally managed framework, distinct from typical Part D mechanisms. The temporary Bridge aims to mitigate immediate risks for plans, while CMS explores potential long-term integration strategies.
In summary, the deferral of the BALANCE model highlights the challenges CMS faces in adapting policy to a rapidly changing pharmaceutical landscape. The agency continues to evaluate the effective integration of GLP-1 weight management drugs into Medicare, considering ongoing shifts in drug pricing and regulatory standards.